These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31669066)

  • 1. Validation of a protein biomarker test for predicting renal decline in type 2 diabetes: The Fremantle Diabetes Study Phase II.
    Peters KE; Davis WA; Ito J; Bringans SD; Lipscombe RJ; Davis TME
    J Diabetes Complications; 2019 Dec; 33(12):107406. PubMed ID: 31669066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Novel Circulating Biomarkers Predicting Rapid Decline in Renal Function in Type 2 Diabetes: The Fremantle Diabetes Study Phase II.
    Peters KE; Davis WA; Ito J; Winfield K; Stoll T; Bringans SD; Lipscombe RJ; Davis TME
    Diabetes Care; 2017 Nov; 40(11):1548-1555. PubMed ID: 28851702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PromarkerD Predicts Renal Function Decline in Type 2 Diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS).
    Peters KE; Xu J; Bringans SD; Davis WA; Davis TME; Hansen MK; Lipscombe RJ
    J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33036174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of biomarkers associated with rapid renal decline in the detection of retinopathy and its progression in type 2 diabetes: The Fremantle Diabetes Study Phase II.
    Drinkwater JJ; Peters K; Davis WA; Turner AW; Bringans SD; Lipscombe RJ; Davis TME
    J Diabetes Complications; 2021 Apr; 35(4):107853. PubMed ID: 33495038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic imaging biomarkers for diabetic kidney disease (iBEAt): study protocol.
    Gooding KM; Lienczewski C; Papale M; Koivuviita N; Maziarz M; Dutius Andersson AM; Sharma K; Pontrelli P; Garcia Hernandez A; Bailey J; Tobin K; Saunavaara V; Zetterqvist A; Shelley D; Teh I; Ball C; Puppala S; Ibberson M; Karihaloo A; Metsärinne K; Banks RE; Gilmour PS; Mansfield M; Gilchrist M; de Zeeuw D; Heerspink HJL; Nuutila P; Kretzler M; Welberry Smith M; Gesualdo L; Andress D; Grenier N; Shore AC; Gomez MF; Sourbron S;
    BMC Nephrol; 2020 Jun; 21(1):242. PubMed ID: 32600374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A panel of novel biomarkers representing different disease pathways improves prediction of renal function decline in type 2 diabetes.
    Pena MJ; Heinzel A; Heinze G; Alkhalaf A; Bakker SJ; Nguyen TQ; Goldschmeding R; Bilo HJ; Perco P; Mayer B; de Zeeuw D; Lambers Heerspink HJ
    PLoS One; 2015; 10(5):e0120995. PubMed ID: 25973922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease.
    Chan L; Nadkarni GN; Fleming F; McCullough JR; Connolly P; Mosoyan G; El Salem F; Kattan MW; Vassalotti JA; Murphy B; Donovan MJ; Coca SG; Damrauer SM
    Diabetologia; 2021 Jul; 64(7):1504-1515. PubMed ID: 33797560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profibrotic Circulating Proteins and Risk of Early Progressive Renal Decline in Patients With Type 2 Diabetes With and Without Albuminuria.
    Ihara K; Skupien J; Kobayashi H; Md Dom ZI; Wilson JM; O'Neil K; Badger HS; Bowsman LM; Satake E; Breyer MD; Duffin KL; Krolewski AS
    Diabetes Care; 2020 Nov; 43(11):2760-2767. PubMed ID: 32887710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria.
    Lee CH; Hui EY; Woo YC; Yeung CY; Chow WS; Yuen MM; Fong CH; Xu A; Lam KS
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1368-75. PubMed ID: 25625802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and pathological predictors of estimated GFR decline in patients with type 2 diabetes and overt proteinuric diabetic nephropathy.
    Mise K; Hoshino J; Ueno T; Hazue R; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Fujii T; Hara S; Ohashi K; Takaichi K; Ubara Y
    Diabetes Metab Res Rev; 2015 Sep; 31(6):572-81. PubMed ID: 25533683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of Plasma Biomarker Candidates for the Prediction of eGFR Decline in Patients With Type 2 Diabetes.
    Heinzel A; Kammer M; Mayer G; Reindl-Schwaighofer R; Hu K; Perco P; Eder S; Rosivall L; Mark PB; Ju W; Kretzler M; Gilmour P; Wilson JM; Duffin KL; Abdalla M; McCarthy MI; Heinze G; Heerspink HL; Wiecek A; Gomez MF; Oberbauer R;
    Diabetes Care; 2018 Sep; 41(9):1947-1954. PubMed ID: 29980527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of the natural history of diabetic kidney disease (DKD).
    Altemtam N; Russell J; El Nahas M
    Nephrol Dial Transplant; 2012 May; 27(5):1847-54. PubMed ID: 22058177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Leucine-Rich α-2-Glycoprotein 1 Predicts Rapid eGFR Decline and Albuminuria Progression in Type 2 Diabetes Mellitus.
    Liu JJ; Pek SLT; Ang K; Tavintharan S; Lim SC;
    J Clin Endocrinol Metab; 2017 Oct; 102(10):3683-3691. PubMed ID: 28973352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of a validated prognostic plasma protein biomarker test for renal decline in type 2 diabetes to type 1 diabetes: the Fremantle Diabetes Study Phase II.
    Davis TME; Davis WA; Bringans SD; Lui JKC; Lumbantobing TSC; Peters KE; Lipscombe RJ
    Clin Diabetes Endocrinol; 2024 Oct; 10(1):30. PubMed ID: 39385270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma Biomarkers and Kidney Function Decline in Early and Established Diabetic Kidney Disease.
    Coca SG; Nadkarni GN; Huang Y; Moledina DG; Rao V; Zhang J; Ferket B; Crowley ST; Fried LF; Parikh CR
    J Am Soc Nephrol; 2017 Sep; 28(9):2786-2793. PubMed ID: 28476763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intra-individual variability of eGFR trajectories in early diabetic kidney disease and lack of performance of prognostic biomarkers.
    Kerschbaum J; Rudnicki M; Dzien A; Dzien-Bischinger C; Winner H; Heerspink HL; Rosivall L; Wiecek A; Mark PB; Eder S; Denicolò S; Mayer G
    Sci Rep; 2020 Nov; 10(1):19743. PubMed ID: 33184434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development.
    Nowak N; Skupien J; Smiles AM; Yamanouchi M; Niewczas MA; Galecki AT; Duffin KL; Breyer MD; Pullen N; Bonventre JV; Krolewski AS
    Kidney Int; 2018 May; 93(5):1198-1206. PubMed ID: 29398132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Prognosis of Patients With Type 2 Diabetes and Nonalbuminuric Diabetic Kidney Disease Is Not Always Poor: Implication of the Effects of Coexisting Macrovascular Complications (JDDM 54).
    Yokoyama H; Araki SI; Kawai K; Yamazaki K; Shirabe SI; Sugimoto H; Minami M; Miyazawa I; Maegawa H;
    Diabetes Care; 2020 May; 43(5):1102-1110. PubMed ID: 32144168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Targeted Multiomics Approach to Identify Biomarkers Associated with Rapid eGFR Decline in Type 1 Diabetes.
    Limonte CP; Valo E; Montemayor D; Afshinnia F; Ahluwalia TS; Costacou T; Darshi M; Forsblom C; Hoofnagle AN; Groop PH; Miller RG; Orchard TJ; Pennathur S; Rossing P; Sandholm N; Snell-Bergeon JK; Ye H; Zhang J; Natarajan L; de Boer IH; Sharma K
    Am J Nephrol; 2020; 51(10):839-848. PubMed ID: 33053547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum kidney injury molecule 1 and β
    Colombo M; Looker HC; Farran B; Hess S; Groop L; Palmer CNA; Brosnan MJ; Dalton RN; Wong M; Turner C; Ahlqvist E; Dunger D; Agakov F; Durrington P; Livingstone S; Betteridge J; McKeigue PM; Colhoun HM;
    Diabetologia; 2019 Jan; 62(1):156-168. PubMed ID: 30288572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.